Innovative solutions to novel drug development in mental health

Neuroscience and Biobehavioral Reviews

Volumn 37, Issue 10, 2013, Pages 2438-2444

  Insel, T R ^a   Voon, V ^b,c   Nye, J S ^d   Brown, V J ^e   Altevogt, B M ^f   Bullmore, E T ^g   Goodwin, G M ^h   Howard, R J ⁱ   Kupfer, D J ^j   Malloch, G ^k   Marston, H M ^l   Nutt, D J ^m   Robbins, T W ^b,c   Stahl, S M ^b,n   Tricklebank, M D ^o   Williams, J H ^p   Sahakian, B J ^b,c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d Neuroscience   (United States)

^e UNIVERSITY OF ST ANDREWS   (United Kingdom)

^f INSTITUTE OF MEDICINE   (United States)

^g ADDENBROOKE S HOSPITAL   (United Kingdom)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

^j UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^k MEDICAL RESEARCH COUNCIL   (United Kingdom)

^l TPP Global Development   (United Kingdom)

^m IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o ELI LILLY AND COMPANY   (United States)

^p WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEVELOPMENTAL BIOLOGY; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG RESEARCH; DRUG TARGETING; GENETIC ASSOCIATION; GENETIC RISK; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; INFORMATION DISSEMINATION; MENTAL HEALTH; MENTAL HEALTH RESEARCH; NERVE CELL DIFFERENTIATION; NERVE CELL NETWORK; NEUROSCIENCE; NOTE; PRIORITY JOURNAL; PSYCHOPATHY; PUBLIC-PRIVATE PARTNERSHIP; TRAINING; TRANSLATIONAL RESEARCH; TREATMENT PLANNING;

BACK-TRANSLATION; BIOMARKERS; COGNITIVE AND PSYCHOSOCIAL TREATMENTS; NEUROBIOLOGICAL MECHANISMS; NEUROPSYCHIATRIC DISORDERS; NOVEL DRUG DEVELOPMENT; PHARMACOLOGICAL TOOL BOX; TRANSLATION;

ANIMALS; BIOLOGICAL MARKERS; BRAIN; DRUG DISCOVERY; EARLY MEDICAL INTERVENTION; HUMANS; MENTAL DISORDERS; MOLECULAR TARGETED THERAPY; RESEARCH SUPPORT AS TOPIC;

EID: 84890235819     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2013.03.022     Document Type: Note

References (48)

1. Beddington J., et al. The mental wealth of nations. Nature 2008, 455:1057-1060.
2. Bloom, D.E., et al., 2011. The Global Economic Burden of Non-communicable Diseases, Geneva.
3. Bodick N.C., et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch. Neurol. 1997, 54:465-473.
4. Brennand K.J., et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011, 473:221-225.
5. Brown V.J., Bowman E.M. Rodent models of prefrontal cortical function. Trends Neurosci. 2002, 25:340-343.
6. Bullmore E., et al. Why psychiatry can't afford to be neurophobic. Br. J. Psychiatry 2009, 194:293-295.
7. Carter C.S., et al. Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biol. Psychiatry 2008, 64:4-10.
8. Collins P.Y., et al. Grand challenges in global mental health. Nature 2011, 475:27-30.
9. Cressey D. Translational research: talking up translation. Nature 2010, 463:422-423.
10. Dias R., et al. Dissociable forms of inhibitory control within prefrontal cortex with an analog of the Wisconsin Card Sort Test: restriction to novel situations and independence from "on-line" processing. J. Neurosci. 1997, 17:9285-9297.
11. Diazgranados N., et al. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 2010, 67:793-802.
12. Drevets W.C., Furey M.L. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol. Psychiatry 2010, 67:432-438.
13. Drevets W.C., et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997, 386:824-827.
14. Eagger S.A., et al. Tacrine in Alzheimer's disease. Lancet 1991, 338:50-51.
15. Goetghebeur P., Dias R. Comparison of haloperidol risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat-a back translational study. Psychopharmacology (Berl) 2009, 202:287-293.
16. Hampshire A., Owen A.M. Fractionating attentional control using event-related fMRI. Cereb. Cortex 2006, 16:1679-1689.
17. Holtzheimer P.E., Mayberg H.S. Deep brain stimulation for psychiatric disorders. Annu. Rev. Neurosci. 2011, 34:289-307.
18. Insel T., et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am. J. Psychiatry 2010, 167:748-751.
19. Insel T.R. Translating scientific opportunity into public health impact: a strategic plan for research on mental illness. Arch. Gen. Psychiatry 2009, 66:128-133.
20. Insel T.R., Sahakian B.J. Drug research: a plan for mental illness. Nature 2012, 483:269.
21. Kessler R.C., et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 2005, 62:593-602.
22. Lander E.S. Initial impact of the sequencing of the human genome. Nature 2011, 470:187-197.
23. Lehner T., Insel T. Psychiatric education in the genomic era. Acad Psychiatry 2010, 34:87-89.
24. Lewis D.A., et al. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am. J. Psychiatry 2008, 165:1585-1593.
25. Maher-Edwards G., et al. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease. Curr. Alzheimer Res. 2010, 7:374-385.
26. Miller G. Is pharma running out of brainy ideas?. Science 2010, 329:502-504.
27. Nutt D., Goodwin G. ECNP Summit on the future of CNS drug research in Europe 2011: report prepared for ECNP by David Nutt and Guy Goodwin. Eur. Neuropsychopharmacol. 2011, 21:495-499.
28. Patil S.T., et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 2007, 13:1102-1107.
29. Pinard E., et al. Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfon yl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. J. Med. Chem. 2010, 53:4603-4614.
30. Preskorn S.H., et al. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J. Clin. Psychopharmacol. 2008, 28:631-637.
31. Rabiner E.A., et al. Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans. Mol. Psychiatry 2011, 16(785):826-835.
32. Ressler K.J., Mayberg H.S. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat. Neurosci. 2007, 10:1116-1124.
33. Ressler K.J., et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch. Gen. Psychiatry 2004, 61:1136-1144.
34. Ripke S., et al. Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 2011, 43:969-976.
35. Sahakian, B.J., 2011. Chapter 3.1: Neuroscience and Society, Brainwaves Module 1: Neuroscience, Society and Policy. The Royal Society, pp. 61-69.
36. Sahakian B.J., et al. A UK strategy for mental health and wellbeing. Lancet 2010, 375:1854-1855.
37. Sanislow C.A., et al. Developing constructs for psychopathology research: research domain criteria. J. Abnorm. Psychol. 2010, 119:631-639.
38. Sankaran V.G., et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 2008, 322:1839-1842.
39. Schwartz J.C. The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br. J. Pharmacol. 2011, 163:713-721.
40. Shaw P., et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:19649-19654.
41. Sklar P., et al. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat. Genet. 2011, 43:977-983.
42. Thornicroft G. Most people with mental illness are not treated. Lancet 2007, 370:807-808.
43. Tobe B.T., et al. Modeling complex neuropsychiatric disorders with human induced pluripotent stem cells. Curr. Opin. Pharmacol. 2011, 11:521-527.
44. Tran P., et al. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J. Psychiatr. Res. 2011, 46:64-71.
45. Tregellas J.R., et al. Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Biol. Psychiatry 2011, 69:7-11.
46. Turner D.C., et al. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 2004, 29:1363-1373.
47. Zarate C., et al. Glutamatergic modulators: the future of treating mood disorders?. Harv. Rev. Psychiatry 2010, 18:293-303.
48. Zarate C.A., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006, 63:856-864.